

THIS SHEET HAS BEEN
REPLACED

ABSTRACT

This invention relates to novel biologically
active molecules which bind to and inhibit thrombin.
Specifically, these molecules are characterized by a
5 thrombin anion-binding exosite association moiety
(ABEAM); a linker portion of at least 18Å in length;
and a thrombin catalytic site-directed moiety (CSDM).
This invention also relates to compositions,
combinations and methods which employ these molecules
10 for therapeutic, prophylactic and diagnostic purposes.

This Sheet Has Been Replaced

